Metlay J P, Waterer G W, Long A C, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of America [J]. Am J Respir Crit Care Med, 2019, 200(7): e45-e67.
Wang H, Liu H, Lou M, et al. Comprehensive clinical evaluation of moxifloxacin: a retrospective study [J]. Medicine (Baltimore), 2023, 102(22): e33896.
Li Y, Zhu D, Peng Y, et al. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia [J]. Curr Med Res Opin, 2021, 37(4): 693-701.
[8]
Sulai N H, Tefferi A. Why does my patient have thrombocytosis? [J]. Hematol Oncol Clin North Am, 2012, 26(2): 285-301.
[9]
Moore J, Baer M R, Grover B E, et al. Moxifloxacin-induced thrombocytopenia mediated by moxifloxacin-dependent IgM and IgG antiplatelet antibodies: a case report [J]. Cureus, 2020, 12(9): e10507.
[10]
Starr J A, Ragucci K R. Thrombocytopenia associated with intravenous ciprofloxacin [J]. Pharmacotherapy, 2005, 25(7): 1030-1034.
[11]
Cheah C Y, Keulenaer B, Leahy M F. Fluoroquinolone-induced immune thrombocytopenia: a report and review [J]. Intern Med J, 2009, 39(9): 619-623.
[12]
Aster R H, Curtis B R, Mcfarland J G, et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management [J]. J Thromb Haemost, 2009, 7(6): 911-918.
2024, Vol. 35 
